Abstract
Background Osteoporosis is a common complication of chronic liver diseases especially associated with Primary biliary cholangitis (PBC). Its occurrence during others autoiummune hepatopathies such us autoimmune hepatitis, primary sclerosing cholangitis has been described. Objectives The aim of our study was to assess the prevalence of osteoporosis in patients with autoimmune hepatopathies. Methods We carried out a retrospective study from January 1996 to December 2018, including all patients with auto-immune hepatopathy [autoimmune hepatitis/Primary biliary cholangitis (PBC)/Primary sclerosing cholangitis (PSC)/overlap syndrome]. Only patients who had bone mineral density (BMD) were selected. Results During the study period, 124 patients were included. The mean age of our patients was 55 years [18-87]. BMD has been realised in 51 patient [32 PBC/5AIH/3PSC/11 overlap Syndrome]. It was normal in 18 cases (35%), whereas 9 patients had osteopenia (18%) and 24 had osteoporosis (47%)[15PBC/2AIH/5overlap/2PSC]. The mean values of L2-L4 T-scores and femur total T-scores were -3.27 and -1.97, respectively., Osteoporotic patients had an average age of 58 years: 1 men, 3 premenopausal, and 20 postmenopausal women. The study of risk factors of osteoporosis has shown that 5patients underwent systemic corticosteroid. A tobacco intoxication has been noted in 1patient. Biochemical analysis indicated a high level of cytolysis (superior to twice normal value) in 14 patient. Cholestasis was noted in 10 patients. The mean values of bilirubin was 23mg/l. Among the 24 patients with osteoporosis, 10 had positif antinuclear antibodies, 17 had positif anti-mitochondrial antibodies and 5 had positif anti-smooth muscle antibodies. Eight of patients were at an advanced stages of liver fibrosis at the moment of diagnosis. Conclusion Our study has shown that autoimmune liver diseases has an influence on bone mineral density as a bone nineral loss was noted in more than half of the cases. It should be considered for all patients with auto immune hepatopathy especially with long duration of corticosteroid treatment. Disclosure of Interests None declared
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
